ZA9610840B - Novel binding agents and the use thereof - Google Patents

Novel binding agents and the use thereof

Info

Publication number: ZA9610840B
Authority: ZA; South Africa
Prior art keywords: cac; arg; identified; amino acids; letter code
Prior art date: 1995-12-27

Application number

ZA9610840A

Other languages

English (en)

Inventor

Eva Turley

Original Assignee

Hyal Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-27

Filing date

1996-12-23

Publication date

1997-06-27

1996-12-23 Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp

1997-06-27 Publication of ZA9610840B publication Critical patent/ZA9610840B/xx

Links

239000011230 binding agent Substances 0.000 title abstract 4
150000001413 amino acids Chemical class 0.000 abstract 4
239000003814 drug Substances 0.000 abstract 4
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229920002674 hyaluronan Polymers 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
229940124597 therapeutic agent Drugs 0.000 abstract 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 1
229940099552 hyaluronan Drugs 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Immunology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

ZA9610840A 1995-12-27 1996-12-23 Novel binding agents and the use thereof ZA9610840B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002166155A CA2166155C (fr)	1995-12-27	1995-12-27	Liaison d'agents aux domaines de liaison de l'acide hyaluronique et son utilisation

Publications (1)

Publication Number	Publication Date
ZA9610840B true ZA9610840B (en)	1997-06-27

Family

ID=4157242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9610840A ZA9610840B (en)	1995-12-27	1996-12-23	Novel binding agents and the use thereof

Country Status (15)

Country	Link
EP (1)	EP0874624B1 (fr)
JP (1)	JP4210330B2 (fr)
KR (1)	KR100476782B1 (fr)
AT (1)	ATE255411T1 (fr)
AU (1)	AU725478B2 (fr)
BR (1)	BR9612355A (fr)
CA (1)	CA2166155C (fr)
DE (1)	DE69630974T2 (fr)
ES (1)	ES2211996T3 (fr)
HU (1)	HU226598B1 (fr)
IL (1)	IL124828A0 (fr)
NO (1)	NO982935L (fr)
PL (1)	PL327542A1 (fr)
WO (1)	WO1997024111A2 (fr)
ZA (1)	ZA9610840B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2237051A1 (fr) *	1997-12-19	1999-06-19	Eva A. Turley	Affinite amelioree de peptides lies a l'hyaluronan
SE0101854L (sv) *	2001-05-28	2002-11-29	Bioneris Ab	Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
WO2004060404A1 (fr) *	2002-12-27	2004-07-22	Chugai Seiyaku Kabushiki Kaisha	Vecteur de medicament
CA2610791C (fr) *	2005-06-08	2015-12-01	Cangene Corporation	Peptides de liaison a l'acide hyaluronique pour ameliorer les defenses de l'organisme hote contre les bacteries pathogenes
JP6153467B2 (ja)	2010-05-31	2017-06-28	ロンドンヘルスサイエンシーズセンターリサーチインコーポレイテッドＬｏｎｄｏｎＨｅａｌｔｈＳｃｉｅｎｃｅｓＣｅｎｔｒｅＲｅｓｅａｒｃｈＩｎｃ．	Ｒｈａｍｍ結合ペプチド
KR101383941B1 (ko) *	2012-03-09	2014-04-10	동아에스티 주식회사	피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
WO2014082042A2 (fr)	2012-11-25	2014-05-30	The Regents Of The University Of California	Peptides qui stimulent l'adipogenèse sous-cutanée
WO2015184125A1 (fr)	2014-05-28	2015-12-03	The Regents Of The University Of California	Peptides, compositions et procédés pour stimuler l'adipogenèse sous-cutanée
US10562935B2 (en)	2015-03-20	2020-02-18	London Health Sciences Centre Research Inc.	Stapled peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340994C (fr) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Traitement de maladies et d'etats pathologiques
CA2122551A1 (fr) *	1994-04-29	1995-10-30	Rudolf Edgar Falk	Traitement de l'atherosclerose
GB9207949D0 (en) *	1992-04-09	1992-05-27	Univ Manitoba	Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
AU3159595A (en) *	1994-08-30	1996-03-22	Hyal Pharmaceutical Corporation	Hyaluronic acid and derivatives for modulation of cellular activity

1995
- 1995-12-27 CA CA002166155A patent/CA2166155C/fr not_active Expired - Lifetime
1996
- 1996-12-23 ZA ZA9610840A patent/ZA9610840B/xx unknown
- 1996-12-23 JP JP52393097A patent/JP4210330B2/ja not_active Expired - Fee Related
- 1996-12-23 AT AT96941564T patent/ATE255411T1/de not_active IP Right Cessation
- 1996-12-23 DE DE69630974T patent/DE69630974T2/de not_active Expired - Lifetime
- 1996-12-23 AU AU10912/97A patent/AU725478B2/en not_active Ceased
- 1996-12-23 PL PL96327542A patent/PL327542A1/xx unknown
- 1996-12-23 WO PCT/CA1996/000870 patent/WO1997024111A2/fr not_active Ceased
- 1996-12-23 EP EP96941564A patent/EP0874624B1/fr not_active Expired - Lifetime
- 1996-12-23 KR KR10-1998-0704359A patent/KR100476782B1/ko not_active Expired - Fee Related
- 1996-12-23 IL IL12482896A patent/IL124828A0/xx not_active IP Right Cessation
- 1996-12-23 ES ES96941564T patent/ES2211996T3/es not_active Expired - Lifetime
- 1996-12-23 HU HU9902059A patent/HU226598B1/hu not_active IP Right Cessation
- 1996-12-23 BR BR9612355-9A patent/BR9612355A/pt not_active Application Discontinuation
1998
- 1998-06-24 NO NO982935A patent/NO982935L/no unknown

Also Published As

Publication number	Publication date
KR100476782B1 (ko)	2005-07-18
AU725478B2 (en)	2000-10-12
CA2166155A1 (fr)	1997-06-28
DE69630974D1 (de)	2004-01-15
PL327542A1 (en)	1998-12-21
BR9612355A (pt)	1999-12-28
ES2211996T3 (es)	2004-07-16
EP0874624A2 (fr)	1998-11-04
HUP9902059A2 (hu)	2000-04-28
WO1997024111A2 (fr)	1997-07-10
IL124828A0 (en)	1999-01-26
NO982935L (no)	1998-08-27
HUP9902059A3 (en)	2000-07-28
HU226598B1 (hu)	2009-04-28
ATE255411T1 (de)	2003-12-15
EP0874624B1 (fr)	2003-12-03
JP4210330B2 (ja)	2009-01-14
NO982935D0 (no)	1998-06-24
AU1091297A (en)	1997-07-28
DE69630974T2 (de)	2004-10-28
JP2000506502A (ja)	2000-05-30
CA2166155C (fr)	2008-02-05
KR19990072058A (ko)	1999-09-27
WO1997024111A3 (fr)	1997-10-02

Publication	Publication Date	Title
NZ504026A (en)	2002-12-20	Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO2001036510A3 (fr)	2002-09-12	Utilisation de polymeres de poli(diallylamine)
BR9813373A (pt)	2000-10-03	Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
ATE434447T1 (de)	2009-07-15	Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
HUT77380A (hu)	1998-04-28	Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
EP0830138A4 (fr)	2000-10-25	Utilisation de facteurs de croissance des fibroblastes pour stimuler la croissance osseuse
MY130157A (en)	2007-06-29	Method of use for inhibiting bone loss and lowering serum cholesterol
RU94027680A (ru)	1996-11-10	Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
BG101118A (en)	1998-04-30	Therapeutical compounds
WO2000021548A3 (fr)	2000-08-31	Dose unitaire de fgf efficace du point de vue angiogenique et methode d'administration
CA2154103A1 (fr)	1997-01-19	Traitement des maladies, traumatismes ou troubles de la membrane muqueuse, et pour le soulagement de la douleur
ZA9610840B (en)	1997-06-27	Novel binding agents and the use thereof
BR9813318A (pt)	2000-08-22	Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ES2160643T3 (es)	2001-11-16	Composiciones que contienen g-csf y proteina de union al tnf.
IL127044A0 (en)	1999-09-22	Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
CA2225788A1 (fr)	1997-01-23	Agents therapeutiques pour maladies auto-immunes
WO1999056666A8 (fr)	2000-08-10	Traitement des troubles de la sexualite chez certains groupes de patients
MY126321A (en)	2006-09-29	Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
YU60199A (sh)	2002-09-19	Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
EP0743068A3 (fr)	1998-06-03	Composition pour inhiber la perte osseuse contentant du sulfate de vanadium
BR0005319A (pt)	2001-07-17	Tratamento combinado para depressão e ansiedade
IL132354A0 (en)	2001-03-19	Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
ZA961419B (en)	1997-08-22	Human DNase I variants.
DE69730967D1 (en)	2004-11-04	Human dnase ii
KR950704358A (ko)	1995-11-20	카텝신 l 특이적 저해 폴리펩티드